Clinical relevance is implicated between the genetic polymorphisms of the ABC (ATP-binding cassette) transporter ABCG2 (ABC subfamily G, member 2) and the individual differences in drug response. We expressed a total of seven nonsynonymous SNP (single nucleotide polymorphism) variants in Flp-In-293 cells by using the Flp (flippase) recombinase system. Of these, ABCG2 F208S and S441N variants were found to be expressed at markedly low levels, whereas their mRNA levels were equal to those of the other SNP variants and ABCG2 WT (wild-type). Interestingly, protein expression levels of the ABCG2 F208S and S441N variants increased 6-to 12-fold when Flp-In-293 cells were treated with MG132, a proteasome inhibitor. Immunoprecipitation followed by immunoblot analysis showed that the ABCG2 F208S and S441N variant proteins were endogenously ubiquitinated in Flp-In-293 cells, and treatment with MG132 significantly enhanced the level of these ubiquitinated variants. Immunofluorescence microscopy demonstrated that MG132 greatly affected the ABCG2 F208S and S441N variants in terms of both protein levels and intracellular distribution. Immunoblot analysis revealed that those variants were N-glycosylated; however, their oligosaccharides were immature compared with those present on ABCG2 WT. The ABCG2 F208S and S441N variant proteins do not appear to be processed in the Golgi apparatus, but undergo ubiquitinmediated protein degradation in proteasomes, whereas ABCG2 WT is sorted to the plasma membrane and then degraded via the lysosomal pathway. The present study provides the first evidence that certain genetic polymorphisms can affect the protein stability of ABCG2. Control of proteasomal degradation of ABCG2 would provide a novel approach in cancer chemotherapy to circumvent multidrug resistance of human cancers.
INTRODUCTION
Human ABCG2 [ABC (ATP-binding cassette) subfamily G, member 2], also known as BCRP (breast cancer resistance protein)/MXR1 (mitoxantrone resistance-associated protein 1)/ ABCP [placenta-specific ABC transporter], is a member of the ABC transporter gene family [1] [2] [3] . It is a so-called 'half ABC transporter' bearing a single ATP-binding fold at the Nterminus and six transmembrane domains. Human ABCG2 exists in the plasma membrane as a homodimer bound through disulfidebonded cysteine residues [4, 5] . Previously, our group and others independently provided direct evidence that Cys 603 is important for human ABCG2 dimer formation [6] [7] [8] [9] .
Overexpression of ABCG2 reportedly confers resistance to anticancer drugs, such as topotecan, irinotecan [CPT (camptothecin) -11] and mitoxantrone, on cancer cells [10] [11] [12] [13] . In the case of drug resistance to irinotecan, SN-38 (7-ethyl-10-hydroxycamptothecin)-resistant PC-6/SN2-5H human lung carcinoma cells were shown to overexpress ABCG2, resulting in reduced intracellular accumulation of SN-38, an active metabolite of CPT-11, and the SN-38-glucuronide conjugate [13] . Indeed, we have proven that ABCG2 transports both SN-38 and SN-38-glucuronide in an ATP-dependent manner [14, 15] . In addition, it has also been reported that ABCG2-transfected cells are resistant to photosensitizers, such as haematoporphyrin, pheophorbide a, and chlorine e6, suggesting a possible role for ABCG2 in cellular resistance to photodynamic therapy [16] . Our high-speed screening and QSAR (quantitative structure-activity relationship) analysis revealed that ABCG2 has high affinities towards haematoporphyrin and pheophorbide a [17] . Furthermore, we provided direct evidence that ABCG2 transports haematoporphyrin in an ATP-dependent manner [18] .
SNPs (single nucleotide polymorphisms) of the ABCG2 gene have been suggested to be a significant factor in the responses of patients to medication and/or the risk of disease [19] [20] [21] [22] [23] [24] . Sequencing of the ABCG2 gene from human samples has revealed over 80 different naturally occurring sequence variations [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . Among them, a total of 17 non-synonymous polymorphisms have been reported for the ABCG2 gene [21] . We have functionally validated those SNP variants. On the basis of our functional validation, the above-mentioned non-synonymous polymorphisms, as well as the acquired mutants (R482G and R482T) of ABCG2 were classified into four groups [33] . The ABCG2 non-synonymous SNP variants Q126stop, F208S, S248P, E334stop, S441N and F489L were defective in the active transport of methotrexate and haematoporphyrin [18] . Furthermore, the F208S, S248P, F431L, S441N, and F489L ABCG2 variants exhibited greatly altered protein expression levels and drug resistance profiles [33] . In particular, the expression levels of the F208S and S441N ABCG2 variant proteins were markedly low. It was hypothesized that such reduced protein levels are associated with the instability and/or degradation of those variant proteins [33] . Nevertheless, the mechanism underlying the low expression levels of those ABCG2 variants (i.e. F208S and S441N) has not yet been elucidated.
The ER (endoplasmic reticulum) is the site where newly synthesized secretory and membrane proteins are folded and assembled under a stringent quality control system. Efficient quality control systems have evolved to prevent incompletely folded molecules from moving along the secretory pathway. Accumulation of misfolded proteins in the ER would detrimentally affect cellular functions. It is likely that misfolded ABCG2 proteins are removed from the ER by retrotranslocation to the cytosol compartment, followed by degradation by the ubiquitin-proteasome system [9, 34] . This process is known as ERAD (ER-associated degradation). In the present paper, we examined the potential link between non-synonymous SNPs and the stability of ABCG2 protein. We provide direct evidence that ABCG2 non-synonymous SNP variants, i.e., F208S and S441N, undergo ubiquitin-mediated protein degradation in proteasomes.
MATERIALS AND METHODS

Chemicals and biological reagents
L-Glutamine was purchased from Wako Pure Chemical Industries, and Tris and high-glucose DMEM (Dulbecco's modified Eagle's medium) were bought from Nacalai Tesque, Kyoto, Japan. FCS (fetal calf serum) was bought from ICN Biomedicals; antibiotic/antimycotic cocktail solution and hygromycin B were purchased from Invitrogen, and MG132 was bought from Sigma. Endo H (endoglycosidase H) and PNGase F (peptide N-glycosidase F) were from New England Biolabs, and Complete TM protease inhibitor cocktail was purchased from Roche. BMA (bafilomycin A 1 ) was a gift from Professor Keiji Hasumi (Department of Applied Biological Science, Tokyo Noko University, Fuchu, Tokyo, Japan). All other chemicals used were of analytical grade.
Flp-In-293 cells expressing ABCG2 WT (wild-type), F208S or S441N
Flp-In-293 cells expressing ABCG2 WT, F208S or S441N, named Flp-In-293/ABCG2 (WT), Flp-In-293/ABCG2 (F208S) or Flp-In-293/ABCG2 (S441N) respectively, were prepared as described previously [8, 33] . Those cells were maintained in highglucose DMEM supplemented with 10 % (v/v) heat-inactivated FCS, 2 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, 250 ng/ml amphotericin B and 100 µg/ml hygromycin B at 37
• C in a humidified atmosphere of 5 % (v/v) CO 2 in air. The number of viable cells was determined from counts made in a haemocytometer by using Trypan Blue dye exclusion.
Detection of mRNA by RT-PCR (reverse transcription-PCR)
Total RNA was extracted from cultured cells with NucleoSpin ® RNA II (Macherey-Nagel, Duren, Germany) according to the manufacturer's protocol. cDNA was prepared from the extracted RNA in a reverse transcriptase reaction using the High Capacity cDNA Archive kit (Applied Biosystems) and random hexamers according to the manufacturer's instructions. The mRNA levels of ABCG2 and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) were determined by PCR in an iCycler TM thermal cycler (Bio-Rad) with the following specific primers: ABCG2 5 -GATCTCTCACCCTGGGGCTTGTGGA-3 and 5 -TGTGCAACAGTGTGATGGCAAGGGA-3 , and GAPDH 5 -ACTGCCAACGTGTCAGTGGTGGACCTGA-3 and 5 -GG-CTGGTGGTCCAGGGGTCTTACTCCTT-3 . The PCR reaction consisted of a hot-start incubation at 94
• C for 2 min, followed by 94
• C for 30 s, 59
• C for 30 s and 72
• C for 30 s for 30 cycles. The PCR products were then analysed by 1.2 % (w/v) agarose gel electrophoresis and detected under UV light by using ethidium bromide.
Immunoblotting to detect ABCG2 proteins
The ABCG2 protein expressed in Flp-In-293 cells was detected by immunoblotting with a specific mouse monoclonal antibody against human ABCG2 (BXP-21; Alexis Biochemicals). Cells were rinsed with ice-cold PBS (without both Ca 2+ and Mg 2+ ) and subsequently treated with lysis buffer containing 50 mM Tris/HCl (pH 7.4), 1 % (w/v) Triton X-100, 1 mM DTT (dithiothreitol) and Complete TM protease inhibitor cocktail for 30 min at 4
• C. The samples were homogenized by passage through a 27 gauge needle and then centrifuged at 800 g for 10 min at 4
• C. For glycosidase treatment, 20 µg of the cell lysate sample was incubated with 20 units of endo H or PNGase F at 37
• C for 10 min. Equal amounts of the resulting cell lysate (10 µg of protein) were subjected to SDS/PAGE (7.5 % gels) in the presence or absence of 10 % (v/v) ME (2-mercaptoethanol). Briefly, proteins were separated by electrophoresis on polyacrylamide gels and then electroblotted on to Hybond-ECL (enhanced chemiluminescence) nitrocellulose membranes (Amersham Biosciences). Immunoblotting was performed by using mouse monoclonal anti-ABCG2 (BXP-21, 1:200 dilution) in TBS (Tris-buffered saline) containing 5 % (w/v) skimmed milk and 0.05 % Tween 20, followed by HRP (horseradish peroxidase)-conjugated horse anti-mouse IgG (1:3000 dilution; Cell Signaling Technology). HRP-dependent luminescence was developed by using Western Lighting Chemiluminescent Reagent Plus (PerkinElmer), following the manufacturer's instructions, and detected in a Lumino Imaging Analyzer FAS-1000 (Toyobo, Osaka, Japan). To detect GAPDH, used as an internal loading control, immunoblot detection was carried out in the same manner as described above except for the use of mouse monoclonal anti-GAPDH antibody (1:1000 dilution; American Research Products, Belmont, MA, U.S.A.) as the primary antibody.
On the basis of the amino acid sequence of human ABCG2 (GenBank accession number NM 004827), the molecular mass of non-glycosylated ABCG2 WT was calculated to be 72314 Da by using the ExPASY Compute pI/Mw tool (http://us.expasy. org/tools/pi tool.html). This molecular mass refers to the nonglycosylated nascent peptide (monomer) of ABCG2.
Immunoprecipitation
To detect ubiquitinated ABCG2 proteins, Flp-In-293 cells expressing ABCG2 in a 100 mm culture dish (3 × 10 6 cells) were pre-cultured for 24 h at 37
• C and then incubated in the presence or absence of 2 µM MG132 for 24 h at 37
• C. Subsequently, ABCG2-expressing Flp-In-293 cells were harvested by centrifugation at 300 g for 5 min at 20
• C and rinsed with ice-cold PBS (without both Ca 2+ and Mg 2+ ). The cells were then treated with immunoprecipitation buffer [20 mM Tris/HCl (pH 7.4), 150 mM NaCl, 1 % (w/v) Triton X-100, 10 µM MG132 and Complete TM protease inhibitor cocktail]. The samples were homogenized by passage through a 27 gauge needle and then centrifuged at 800 g for 10 min at 4
• C. The resulting cell lysate (1 mg of protein) was incubated with an equal amount of Preclearing Matrix E (Santa Cruz Biotechnology) for 1 h at 4
• C with gentle agitation. After centrifugation (17 800 g for 1 min at 4
• C), the resulting supernatant was used for immunoprecipitation as described below.
Immunoprecipitation experiments were performed as described previously [34] . Briefly, the mouse monoclonal ABCG2-specific antibody (BXP-21, 1:125 dilution) or mouse monoclonal antiubiquitin antibody (1:500 dilution; Millipore) was incubated at 4
• C for 1 h with gentle agitation with Preclearing Matrix E (Santa Cruz Biotechnology) in TBS with 0.1 % BSA in order to form the antibody-immunoprecipitate matrix complex. The resulting antibody-immunopreciptate matrix complex and pre-incubated cell lysates were mixed and then further incubated overnight at 4
• C with gentle agitation. The immune complexes were washed with TTBS [TBS with 0.05 % (v/v) Tween 20] and the subsequently immunoprecipitated proteins were eluted with SDS/PAGE sample buffer containing 10 % (v/v) ME. The resulting eluate was subjected to SDS/PAGE (7.5 % gels) and immunoblot analysis. Mouse monoclonal anti-ABCG2 (BXP-21, 1:200 dilution), mouse monoclonal anti-ubiquitin antibody (1:500 dilution) or rabbit polyclonal anti-ubiquitin antibody (1:1000 dilution; EMD Biosciences, Darmstadt, Germany) were used as primary antibodies. Mouse ExactaCruz TM E-HRP (1:1000 dilution; Santa Cruz Biotechnology) or HRP-conjugated goat anti-rabbit IgG conjugate ZyMax TM (1:3000 dilution; Zymed Laboratories) were used as secondary antibodies.
Immunofluorescence analysis for expression levels and distribution of intracellular ABCG2
ABCG2-expressing Flp-In-293 cells (2 × 10 4 cells) were seeded on to 96-well SensoPlates TM (Greiner Bio-One) in which the bottom of each well had been coated with mouse collagen type IV (BD Biosciences) at a density of 1.6 µg/well. In the wells, cells were pre-cultured for 24 h at 37
• C under the above-mentioned culture conditions and then incubated in the presence or absence of 2 µM MG132 for 24 h at 37
• C. Cells were then fixed with 4 % (w/v) paraformaldehyde in PBS (without both Ca 2+ and Mg 2+ ) at room temperature (22) (23) (24) (25) • C) for 20 min and then cell membranes were permeabilized by incubation with 0.02 % Triton X-100 in PBS (without both Ca 2+ and Mg 2+ ) at room temperature for 5 min. To block free aldehyde groups present in the formaldehyde, cells were treated with glycine (10 mg/ml) in PBS (without both Ca 2+ and Mg 2+ ) at room temperature for 10 min, followed by a further incubation with 0.5 % BSA in PBS (without both Ca 2+ and Mg 2+ ) at room temperature for 1 h. To detect the ABCG2 protein, cells were treated with mouse monoclonal anti-ABCG2 antibody (BXP-21, 1:1000 dilution) as the primary antibody, and subsequently with Alexa Fluor ® 488-conjugated anti-mouse IgG antibody (1:1000 dilution; Invitrogen).
To detect selectively the ABCG2 protein localized on the plasma membrane of cells, we used the monoclonal ABCG2-specific antibody 5D3 (1:1000 dilution; R&D Systems) as the primary antibody, since it reacts with an epitope present in the extracellular loop of ABCG2 [35] . During the incubation with 5D3, we avoided using 0.02 % Triton X-100 in order to keep the plasma membrane impermeable to the antibody. In the same preparations, nuclear DNA was stained with Hoechst 33342 (1 µg/ml; Invitrogen) in PBS (without both Ca 2+ and Mg 2+ ) containing 0.5 % BSA.
Immunofluorescence of the Flp-In-293 cells was detected with a newly developed system of confocal fluorescence microscopy (Yokogawa Electric Corporation, Kanazawa, Japan). The fluorescences of Alexa Fluor ® 488 and Hoechst 33342 were observed by using an excitation laser light at 488 and 405 nm wavelengths respectively. To analyse quantitatively the distribution of the ABCG2 protein localized on the plasma membrane or in the cytosol, the immunofluorescence images captured by the confocal fluorescence microscopy system were processed by means of originally-developed computer software, where a single immunofluorescent cluster with a diameter of 0.5 to 10 µm was counted as one ABCG2 positive dot. Such digital counting of ABCG2 positive dots was performed over 400 cells for each immunofluorescence preparation. The resulting values were accumulated and then statistically analysed.
Statistical analysis
Statistical analyses were performed by using Microsoft Excel 2003 software (Microsoft). The statistical significance of differences was determined according to the Student's t test, where P < 0.05 was considered to be statistically significant. Figure 1 (A) depicts a schematic illustration of the human ABCG2 protein in order to show the sites of amino acid alteration in the ABCG2 SNP variants F208S and S441N. WT, F208S and S441N ABCG2 were individually expressed in Flp-In-293 cells by using the Flp (flippase) recombinase system [8, 33] . As shown in Figure 1 (B), mRNA levels of ABCG2 WT, as well as F208S and S441N variants, were evenly represented in Flp-In-293 cells, where the mRNA levels of ABCG2 and GAPDH were determined by RT-PCR. WT, F208S and S441N ABCG2, as well as GAPDH, were also detected by immunoblotting, and their expression levels were quantified. For this purpose, we treated all of the samples with PNGase F and ME to remove glycosidase moieties and to break the cysteinyl disulfide bond which forms an ABCG2 homodimer. Since there was a linear relationship between the signal intensity of immunoblotting and the logarithmic value of the amount of ABCG2 protein analysed by electrophoresis [36] , the expression level of ABCG2 or GAPDH in the cell lysate samples could be quantitatively estimated based on this linear relationship. The relative values of protein levels were then normalized to the ratio of ABCG2 WT/GAPDH. Although mRNA levels were almost identical in ABCG2 WT and the SNP variants (F208S and S441N), the protein levels of those SNP variants were markedly low ( Figure 1B ). This resulted in the fundamental question as to what was the molecular mechanism involved in reducing the protein level of those SNP variants.
RESULTS
Protein expression levels of ABCG2 WT, F208S, and S441N in Flp-In-293 cells
Characterization of F208S and S441N variants expressed in Flp-In-293 cells
To gain insight into the molecular nature of ABCG2 WT and the two SNP variants (F208S and S441N) , we performed immunoblot analysis experiments with cell lysate samples under reduced or non-reduced conditions. Figure 2(A) shows the effect of ME treatment on the migration of ABCG2 WT, F208S and S441N proteins on SDS/PAGE. When the cell lysate samples from FlpIn-293 cells expressing those proteins were applied to SDS/PAGE without ME treatment, one major band was observed at 162 kDa for those ABCG2 proteins. In contrast, treatment with ME reduced the apparent molecular mass of those protein bands by half. These results suggest that the ABCG2 F208S and S441N proteins form homodimers through a cysteinyl disulfide bond, as observed for the WT ABCG2 protein.
It is important to note, however, that there were significant differences among ABCG2 WT and those SNP variants with respect to the protein band patterns. As demonstrated in the ME(+) panel (Figure 2A, lower panel) , two bands were detected at molecular masses of approx. 81 kDa (major band) and 74 kDa (minor band) in the cell lysate sample prepared from Flp-In-293/ABCG2 (WT) cells. On the other hand, for the S441N ABCG2 variant, two forms of ABCG2 were detected at a molecular mass of approx. 81 kDa. In the case of the ABCG2 F208S variant, one faint band was detected at an apparent molecular mass of 74 kDa by the same sample processing and immunoblotting experiment.
As demonstrated in Figure 2 (B), PNGase F treatment of those cell lysate samples resulted in one major band with a molecular mass of 72 kDa, suggesting that glycosylation occurred at an asparagine moiety, most probably Asn 596 (results not shown). Thus the 72 kDa protein band is regarded as the non-glycosylated form of ABCG2; however, endo H treatment gave different results. Although the 81 kDa major band of ABCG2 WT was not at all affected by endo H treatment, the apparent molecular masses of the smaller protein bands of ABCG2 F208S (74 kDa) and S441N (78 kDa) decreased after endo H treatment. F208S and S441N, their N-linked oligosaccharide structures appear to be different. The mature N-linked oligosaccharide of ABCG2 WT may have a structure which is resistant to endo H, whereas the immature N-linked oligosaccharides of the F208S and S441N variant proteins are susceptible to this endoglycosidase.
Effect of MG132 and BMA on the protein expression levels of F208S and S441N variants
We hypothesize that the low protein expression levels of the F208S and S441N variants are due to rapid degradation of those proteins through ubiquitin-mediated proteasomal proteolysis. We therefore investigated the effect of MG132, an inhibitor of proteasomal proteolysis, on the protein expression levels of those SNP variants. Flp-In-293 cells expressing ABCG2 F208S or S441N were incubated in the presence of 0, 0.4 or 2.0 µM MG132 for 24 h, and then cell lysate samples were immediately prepared. Protein expression levels of the F208S and S441N variants were determined by immunoblotting after PNGase F treatment as described above.
As shown in Figure 3 (A), the protein levels of those ABCG2 variants were remarkably enhanced by the treatment with the proteasome inhibitor MG132 in a concentration-dependent manner. In contrast, the protein level of ABCG2 WT was not significantly affected by MG132 treatment ( Figure 3C ). After 24 h treatment with 2 µM MG132, ABCG2 F208S and S441N protein levels were increased 12-and 6-fold respectively. It is of interest to note that MG132 treatments enhanced the levels of the non-glycosylated form (72 kDa) for both the F208S and S441N variants when those cell lysate samples were not treated with PNGase F ( Figure 3A ). More importantly, on immunoblot analysis without PNGase F treatment, aggregated forms (arrowheads in Figure 3B ) of both the ABCG2 F208S and S441N variants were detected in the high-molecular-mass range (over 200 kDa). Figure 3 (C) demonstrates a clear difference between MG132 and BMA with respect to their effects on protein expression levels of ABCG2 WT and those SNP variants. The protein level of ABCG2 WT increased more than 2.5-fold when cells were treated with BMA, which inhibits lysosomal degradation, whereas the ABCG2 F208S and S441N variant proteins were minimally affected by the same treatment. The effect of BMA conspicuously differed from that of MG132 ( Figure 3C ). In addition, no aggregated forms were detected in ABCG2 WT after 24 h incubation with BMA (results not shown).
Effect of MG132 on the ubiquitination states of F208S and S441N variants
To investigate the effect of MG132 on the ubiquitination states of the ABCG2 F208S and S441N variant proteins, FlpIn-293 cells expressing those SNP variants were incubated in the presence or absence of 2 µM MG132 for 24 h. As shown in Figure 4 , significant increases in the ubiquitinated forms of the F208S and S441N variant proteins were detected by immunoblotting with mouse monoclonal anti-ubiquitin antibody after immunoprecipitation with anti-ABCG2 antibody (BXP-21). Similar results were obtained by immunoblotting with BXP-21 after immunoprecipitation with the anti-ubiquitin antibody ( Figures 4A and 4C) . To avoid the strong IgG bands (approx. 80 kDa), we used a rabbit polyclonal anti-ubiquitin antibody to perform the same immunoprecipitation and immunoblotting. The corresponding results are presented in Figures 4(B) and  4(D) , where ubiquitinated forms (arrowheads) appeared to be more prominent than with the monoclonal anti-ubiquitin antibody ( Figures 4A and 4C ). In addition, highly ubiquitinated forms (*) were also observed in the higher-molecular-mass range (150-200 kDa). In contrast, the ubiquitinated state of the ABCG2 WT protein was little affected by MG132 treatment (results not shown).
Effect of MG132 on the cellular localization of F208S and S441N variants
It is of interest to know how inhibition of proteasomal protein degradation by MG132 affects the cellular localization of the ABCG2 F208S and S441N variant proteins. Figure 5 shows immunofluorescence images of Flp-In-293 cells expressing ABCG2 WT, F208S or S441N proteins that has been incubated in the presence or absence of 2 µM MG132 for 24 h. The ABCG2 protein was probed using mouse monoclonal ABCG2 antibodies (either BXP-21 or 5D3 antibodies). By using the BXP-21 antibody that recognizes an epitope (amino acids 271-396) in the intracellular loop of ABCG2, we observed the localization of ABCG2 both at the plasma membrane and within intracellular compartments. In contrast, using the 5D3 antibody that recognizes an epitope in the extracellular loop of ABCG2 [35] , we could only observe the localization of ABCG2 at the plasma membrane.
As demonstrated in Figure 5 , the ABCG2 protein was labelled with a green fluorescent dye (Alexa Fluor ® 488), whereas DNA in the nuclei was stained with Hoechst 33342 (blue fluorescence). In the case of ABCG2 WT, strong green fluorescence was observed at the plasma membrane and within intracellular compartments in Flp-In-293 cells expressing ABCG2 WT (Figures 5a and  5c ). The localization and intensity of ABCG2 WT was not greatly affected by MG132 treatment (Figures 5b and 5d) .
On the other hand, immunofluorescence of the ABCG2 F208S variant was extremely weak at the plasma membrane as well as within intracellular compartments (Figures 5e and 5g) . After Cells were incubated in the presence (+MG132) or absence (none) of 2 µM MG132 for 24 h at 37 • C. ABCG2 proteins were detected by using a mouse monoclonal ABCG2 antibody (either BXP-21 or 5D3) and Alexa Fluor ® 488 (green fluorescence). Cellular nuclei were stained using Hoechst 33342 (blue fluorescence) as described in the Materials and methods section. Scale bar, 10 µm.
MG132 treatment, the localization of the ABCG2 variant protein in intracellular compartments was slightly enhanced (Figure 5f ). However, no localization was observed at the plasma membrane even after MG132 treatment (Figures 5g and 5h ). In the case of the ABCG2 S441N variant, MG132 treatment enhanced the localization of this ABCG2 variant protein at the plasma membrane and in intracellular compartments (Figures 5j and 5l) . Figure 6 depicts the statistical data on the cellular localization of ABCG2 WT and the SNP variants. The results were acquired from a large number of cells, as described below. In each cell, immunofluorescent clusters with a diameter of 0.5 to 10 µm were counted as ABCG2-positive dots. ABCG2-positive dots were counted over 400 cells for each immunofluorescence experiment. Analysis of the digital data is shown in Figure 6(A) , in which the number of cells is represented as a function of ABCG2-positive dots/cell. Remarkable differences were observed after MG132 treatment in terms of the cellular localization and/or the quantity of the F208S or S441N variant ABCG2 proteins as shown in Figure 6 (A). It is noteworthy that protein levels of the F208S and S441N variants were clearly enhanced in intracellular compartments after MG132 treatment, as observed with the BXP-21 antibody. In addition, plasma membrane localization of the S441N variant was also enhanced by MG132 treatment, as observed with the 5D3 antibody. However, no plasma membrane localization was detected in the case of the F208S variant ABCG2 protein ( Figure 6A ). Figure 6 (B) summarizes the abovementioned results, demonstrating the effect of MG132 treatment on the average number of ABCG2-positive dots/cell detected with BXP-21 or 5D3 antibodies, with statistical significances (P < 0.005) in differences indicated (*).
DISCUSSION
Non-synonymous polymorphisms of ABCG2
Accumulating evidence suggests that human ABCG2 plays pivotal roles in mediating drug resistance of cancer cells and affecting the pharmacological behaviour of a variety of drugs. Among the previously reported SNPs in the ABCG2 gene, the frequencies of the Ser 208 and Asn 441 alleles are relatively low (less than 1 %) compared with those of major ABCG2 polymorphisms of the Met 12 and Lys 141 alleles. These Ser 208 and Asn 441 alleles were found only in the Japanese population [28, 29, 37] ; however, their clinical significance in cancer chemotherapy and/or disease risk would be of great interest.
In a previous study using the Flp recombinase system [33] , we functionally characterized the non-synonymous polymorphisms (V12M, Q141K, F208S, S248P, F431L, S441N and F489L ) in terms of their protein expression level, drug resistance profile and prazosin-stimulated ATPase activity. We found that protein expression levels varied among those SNP variants. In particular, the expression levels of the F208S and S441N variant proteins were markedly low (Figure 1) , consistent with the recent report of Yoshioka et al. [37] . Thus it was speculated that such reduced protein levels could be associated with instability and/or degradation of those variant proteins.
Ubiquitin-mediated proteasomal degradation of F208S and S441N variants
In the present study, we undertook the biochemical analysis of the molecular mechanisms underlying the low expression levels of the ABCG2 F208S and S441N variants. It is well known that there are two main routes for protein clearance in eukaryotic cells: the ubiquitin-proteasome and endosome-lysosome pathways. We have recently demonstrated that these two distinct pathways play a pivotal role in the protein degradation of ABCG2 WT and mutants lacking the intra-molecular disulfide bond [34] . Actually, ABCG2 WT is degraded in lysosomes, and the misfolded mutant proteins undergo ubiquitin-mediated protein degradation in proteasomes.
On the basis of those recent findings, we have examined the contribution of ubiquitin-mediated proteasomal degradation to the low-level expression of F208S and S441N ABCG2 variants by testing the effect of MG132. The presence of MG132 increased both the protein levels ( Figure 3 ) and the ubiquitinated forms (Figure 4 ) of the F208S and S441N variant proteins. It is strongly suggested that ubiquitin-mediated proteasomal degradation is the major pathway for those SNP variants.
Misfolded proteins (e.g. ABCG2 F208S and S441N variants) are considered to be removed from the ER by retrotranslocation to the cytosol and then degraded by the ubiquitin-proteasome system by a process known as ERAD [38, 39] . If these misfolded proteins are not degraded in proteasomes (e.g. inhibition by MG132), they are transported into a microtubule-organizing centre together with ubiquitin and ER chaperones to form cytoplasmic aggregates called aggresomes. In fact, ABCG2 appeared to form aggresomes (arrowheads in Figure 3B ) when proteasomal degradation was inhibited by MG132 treatment in Flp-In-293 cells. Observation of the ABCG2 aggresomes by immunoelectron microscopy is presently underway and the relevant results will be reported elsewhere.
N-linked oligosaccharides of ABCG2 F208S and S441N variants
During de novo synthesis in the ER, oligosaccharides are added to asparagine (N-glycosylation) or serine residues (Oglycosylation) of glycoproteins. In the ER and the Golgi, these oligosaccharides are modified and extended in several steps. Nglycosylation is known to play a role in protein stability, targeting to designated sites and in protein activity [40] [41] [42] . ABCG2 is an N-glycosylated protein localized in the plasma membrane. On the basis of sequence analysis, three potential N-linked glycosylation sites, Asn 418 , Asn 557 and Asn 596 , were suggested. Site-directed mutagenesis experiments, in which each asparagine residue was changed to glutamine or alanine, revealed that only Asn 596 is modified by N-linked glycosylation [43, 44] . It was originally assumed that N-linked glycosylation at Asn 596 could be a critical factor for plasma membrane localization of the ABCG2 protein. However, Mohrmann et al. [43] and Diop and Hrycyna [44] provided evidence that N-linked glycosylation of ABCG2 on Asn 596 is not essential for trafficking to the plasma membrane, protein expression or transport activity. Their findings were confirmed by recent experiments in which Asn 596 of the ABCG2 protein was changed to glutamine and expressed in Flp-In-293 cells by using the Flp recombinase system (H. Nakagawa, We have provided evidence that ABCG2 WT and the variants undergo degradation by different pathways. ABCG2 WT is degraded by the endosome-lysosome pathway after remaining in the plasma membrane for a certain period. In contrast, those SNP variants (both non-glycosylated and immature forms) are regarded as misfolded proteins by putative 'check point' systems and readily undergo ubiquitination and protein degradation in proteasomes, as described in detail in the Discussion section.
K. Wakabayashi, A. Tamura, S. Koshiba, Y. Toyoda and T. Ishikawa, unpublished results). In fact, the ABCG2 N596Q protein was not N-glycosylated, but was expressed at lower levels (approximately half of the WT protein level) and localized in the plasma membrane of the cells (results not shown). It is important to note that N-linked oligosaccharide processing was greatly impaired in the ABCG2 F208S and S441N SNP variants. In comparison with the maturely glycosylated ABCG2 WT, those SNP variants appeared to possess immature forms of N-linked oligosaccharides.
Check points for ABCG2 protein quality control in the ER
In the ER, N-linked glycans are added to proteins as 'core oligosaccharides' (Glc 3 Man 9 GlcNAc 2 ), whereas the repertoire of oligosaccharide structures is still rather small. These glycans are therefore subjected to extensive modification as glycoproteins mature and move through the ER via the Golgi apparatus to their final destination, such as the plasma membrane [41] . It is likely, however, that the ABCG2 F208S and S441N variant proteins did not undergo Golgi-apparatus-mediated glycoprocessing, but were passed through the so-called ERAD pathway. The immature and non-glycosylated forms of ABCG2 F208S and S441N were detected when Flp-In-293/ABCG2 (F208S) and FlpIn-293/ABCG2 (S441N) cells were treated with MG132 for 24 h (Figure 3A) , suggesting that those variant proteins were ubiquitinated in both pre-and post-N-glycosylation reactions and then readily degraded in proteasomes. It is known that, in the ER, the N-linked glycans play pivotal roles in protein folding, oligomerization and protein quality control [42] . In this context, we assume that at least two check points exist for ABCG2 protein quality control in the ER (Scheme 1). While we have demonstrated here the ubiquitination and proteasomal degradation of the ABCG2 F208S or S441N variant homodimers, it will be important to study the fate of heterodimers (WT/SNP variant) in the future. At present, there is no information about the degradative pathway followed by heterodimers of ABCG2.
In contrast with those SNP variant proteins, the ABCG2 WT protein undergoes Golgi-apparatus-mediated glycoprocessing, as illustrated in Scheme 1. In the Golgi apparatus, glycans of the ABCG2 WT protein may acquire more complex structures [40, 41] . Analysis of the molecular structure and function of the maturely glycosylated ABCG2 WT will be the next important step in understanding the molecular machinery underlying ABCG2 protein sorting to the plasma membrane and the subsequent lysosome-mediated protein degradation.
Concluding remarks
In this present paper, we provide evidence, for the first time, that there are stringent quality control systems ('check points') that recognize misfolded ABCG2 proteins arising from genetic polymorphisms. The ER is the subcellular site where de novo synthesized nascent proteins acquire their proper tertiary structures. As exemplified by the ABCG2 F208S and S441N variants, it is likely that several other SNP variants may undergo degradation via the ERAD pathway. If the check points for ABCG2 could be controlled, it might be possible to find a novel approach to overcome ABCG2-associated multidrug resistance in cancer chemotherapy.
